SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Clinical trial NCT02455557 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02455557
- Sponsor
- Roswell Park Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-04
- Primary completion
- 2019-10-23
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.